> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Taltz
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-taltz/
- Published: 2018-10-26T12:00:00.000Z
- Updated: 2026-09-15T00:40:51.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142684

*Federal Register* notice: FDA has determined for patent extension-related purposes the regulatory review period for Eli Lilly’s Taltz (ixekizumab), indicated for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The regulatory review period was determined to be 3,036 days, which includes 2,670 days that occurred during the testing phase and 366 days during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-10-26/pdf/2018-23438.pdf?ref=fdaweb.com).